{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreie4utn7abs46ulczib6m7kbaiyyftahx2wz6nxhzu4vvp3qxszqci",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mndglqmc72b2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreialyqtkxxpn3lazptgvkprvtmehzhnyylhq75naxi3wfcjupcy6ze"
    },
    "mimeType": "image/jpeg",
    "size": 543500
  },
  "path": "/news/2026-06-circulating-tumor-dna-benefits.html",
  "publishedAt": "2026-06-02T15:20:01.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "After surgery for colon cancer, many patients face the question of whether follow-up chemotherapy is necessary to prevent a possible relapse. The decision is particularly difficult in so-called Stage II, the intermediate-risk group. Although around one in five untreated patients suffers a relapse, adjuvant chemotherapy places a significant and, in some cases, unnecessary burden on many patients. A clinical study led by Dresden University Hospital now provides important insights for a robust basis for decision-making.",
  "title": "Study on circulating tumor DNA shows clear benefits"
}